Cytek Q1 revenue $44.9M (+21% YoY); organic revenue up 11%; reaffirms 2024 guidance

Cytek Biosciences, Inc.

Total revenue $44.9M, +21% YoY; organic revenue (ex-Luminex) $37.3M, +11%.
Gross profit margin 51% (down from 57%); adjusted gross margin 55% (down from 59%).
Net loss $6.2M vs $6.8M loss; Adjusted EBITDA loss $0.7M vs $2.5M loss.
Reaffirms 2024 revenue guidance $203M-$213M (5-10% growth); expects positive net income for FY2024.
Appointed William McCombe as CFO; opened new facility in Wuxi, China; received NMPA approvals.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cytek Biosciences, Inc. reported the quarter ended March 31, 2024 results: revenue $44.9 million, net income $6.2 million. Guidance reaffirmed.

Period: the quarter ended March 31, 2024
Revenue: $44.9 million
Net income: $6.2 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

(Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 • Organic revenue was $37.3 million, representing an increase of 11% compared to the first quarter of 2023 •

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Cytek Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-134238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.